Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
JAMA Netw Open ; 5(10): e2238154, 2022 10 03.
Article in English | MEDLINE | ID: mdl-36279137

ABSTRACT

Importance: Randomized clinical trials have shown the efficacy of endovascular therapy (EVT) for acute large vessel occlusion strokes. The benefit of EVT in acute stroke with distal, medium vessel occlusion (DMVO) remains unclear. Objective: To examine the efficacy and safety outcomes associated with EVT in patients with primary DMVO stroke when compared with a control cohort treated with medical management (MM) alone. Design, Setting, and Participants: This multicenter, retrospective cohort study pooled data from patients who had an acute stroke and a primary anterior circulation emergency DMVO, defined as any segment of the anterior cerebral artery (ACA) or distal middle cerebral artery, between January 1, 2015, and December 31, 2019. Those with a concomitant proximal occlusion were excluded. Outcomes were compared between the 2 treatment groups using propensity score methods. Data analysis was performed from March to June 2021. Exposures: Patients were divided into EVT and MM groups. Main Outcomes and Measures: Main efficacy outcomes included 3-month functional independence (modified Rankin Scale [mRS] scores, 0-2) and 3-month excellent outcome (mRS scores, 0-1). Safety outcomes included 3-month mortality and symptomatic intracranial hemorrhage. Results: A total of 286 patients with DMVO were evaluated, including 156 treated with EVT (mean [SD] age, 66.7 [13.7] years; 90 men [57.6%]; median National Institute of Health Stroke Scale [NIHSS] score, 13.5 [IQR, 8.5-18.5]; intravenous tissue plasminogen activator [IV tPA] use, 75 [49.7%]; ACA involvement, 49 [31.4%]) and 130 treated with medical management (mean [SD] age, 69.8 [14.9] years; 62 men [47.7%]; median NIHSS score, 7.0 [IQR, 4.0-14.0], IV tPA use, 58 [44.6%]; ACA involvement, 31 [24.0%]). There was no difference in the unadjusted rate of 3-month functional independence in the EVT vs MM groups (151 [51.7%] vs 124 [50.0%]; P = .78), excellent outcome (151 [38.4%] vs 123 [31.7%]; P = .25), or mortality (139 [18.7%] vs 106 [11.3%]; P = .15). The rate of symptomatic intracranial hemorrhage was similar in the EVT vs MM groups (weighted: 4.0% vs 3.1%; P = .90). In inverse probability of treatment weighting propensity analyses, there was no significant difference between groups for functional independence (adjusted odds ratio [aOR], 1.36; 95% CI, 0.84-2.19; P = .20) or mortality (aOR, 1.24; 95% CI, 0.63-2.43; P = .53), whereas the EVT group had higher odds of an excellent outcome (mRS scores, 0-1) at 3 months (aOR, 1.71; 95% CI, 1.02-2.87; P = .04). Conclusions and Relevance: The findings of this multicenter cohort study suggest that EVT may be considered for selected patients with ACA or distal middle cerebral artery strokes. Further larger randomized investigation regarding the risk-benefit ratio for DMVO treatment is indicated.


Subject(s)
Endovascular Procedures , Stroke , Male , Humans , Aged , Tissue Plasminogen Activator/therapeutic use , Retrospective Studies , Cohort Studies , Endovascular Procedures/methods , Treatment Outcome , Stroke/etiology , Intracranial Hemorrhages
2.
Stroke ; 52(5): e117-e130, 2021 05.
Article in English | MEDLINE | ID: mdl-33878892
3.
J Stroke Cerebrovasc Dis ; 29(12): 105353, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33039770

ABSTRACT

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Neurological manifestations related to COVID-19, including acute ischemic Stroke (AIS), have been reported in recent studies. In most of these, the patients are older, have multiple co-morbidities as risk factors for AIS and have developed a severe respiratory illness. Herein, we report a 36-year-old man with no significant past medical history who recently recovered from a mild COVID-19 infection and presented with unusual pattern of arterial macrothrombosis causing AIS. When the AIS happened, he had no COVID-19 related symptoms, had two negative screening tests for the infection and his chest CT was unremarkable.


Subject(s)
Brain Ischemia/etiology , COVID-19/complications , Carotid Stenosis/etiology , Intracranial Thrombosis/etiology , Stroke/etiology , Adult , Age Factors , Anticoagulants/administration & dosage , Brain Ischemia/diagnostic imaging , Brain Ischemia/therapy , COVID-19/diagnosis , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/therapy , Heparin/administration & dosage , Humans , Intracranial Thrombosis/diagnostic imaging , Intracranial Thrombosis/therapy , Male , Stroke/diagnostic imaging , Stroke/therapy , Thrombectomy , Time Factors , Treatment Outcome
4.
Neurosurg Focus ; 42(4): E4, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28366053

ABSTRACT

Despite the success of numerous neuroprotective strategies in animal and preclinical stroke models, none have effectively translated to clinical medicine. A multitude of influences are likely responsible. Two such factors are inefficient recanalization strategies for large vessel occlusions and suboptimal delivery methods/platforms for neuroprotective agents. The recent endovascular stroke trials have established a new paradigm for large vessel stroke treatment. The associated advent of advanced mechanical revascularization devices and new stroke technologies help address each of these existing gaps. A strategy combining effective endovascular revascularization with administration of neuroprotective therapies is now practical and could have additive, if not synergistic, effects. This review outlines past and current neuroprotective strategies assessed in acute stroke trials. The discussion focuses on delivery platforms and their potential applicability to endovascular stoke treatment.


Subject(s)
Drug Delivery Systems , Neuroprotective Agents/administration & dosage , Stroke/therapy , Thrombectomy/methods , Animals , Brain Ischemia/complications , Emergency Medical Services , Humans , Stroke/etiology
5.
Neurosurg Focus ; 37(1 Suppl): 1, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24983724

ABSTRACT

Type 1 spinal dural arteriovenous fistula (dAVF) constitute the vast majority of all spinal vascular malformations. Here we present the case of a 71-year-old male with progressive myelopathy, lower-extremity weakness and numbness, and urinary incontinence. MRI imaging of the thoracic spine demonstrated cord edema, and catheter spinal angiography confirmed a type 1 spinal dAVF. The fistula was supplied by small dural branches of the left L-2 segmental artery. Angiographic cure was achieved with a one-stage procedure in which coils were used to occlude the distal segmental vessels, followed by balloon-assisted embolization with Onyx. The video can be found here: http://youtu.be/8aehJbueH0U .


Subject(s)
Balloon Occlusion/methods , Central Nervous System Vascular Malformations/surgery , Spinal Diseases/surgery , Aged , Angiography , Central Nervous System Vascular Malformations/complications , Central Nervous System Vascular Malformations/diagnosis , Humans , Magnetic Resonance Imaging , Male , Spinal Diseases/complications , Spinal Diseases/diagnosis
6.
Neurosurg Focus ; 37(1 Suppl): 1, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24983725

ABSTRACT

Open surgical disconnection has long been the treatment of choice for dural arteriovenous fistulas (dAVFs) of the anterior cranial fossa. However, advanced patient age and the presence of medical comorbidities can substantially increase the risk of craniotomy and favor a less invasive endovascular approach. Optimal positioning within the distal ophthalmic artery, beyond the origin of the central retinal branch, is achievable using current microcatheter technology and embolic materials. Here we present the case of an 88-year-old female with an incidentally discovered dAVF of the anterior cranial fossa. Angiographic cure was achieved with one-stage Onyx embolization. The video can be found here: http://youtu.be/KVE0fUIECQM .


Subject(s)
Central Nervous System Vascular Malformations/surgery , Cranial Fossa, Anterior/surgery , Embolization, Therapeutic/methods , Aged, 80 and over , Central Nervous System Vascular Malformations/complications , Cerebral Angiography , Embolization, Therapeutic/instrumentation , Female , Humans , Magnetic Resonance Imaging , Ophthalmic Artery/surgery , Polyvinyls , Treatment Outcome , Vision Disorders/etiology
8.
Int J Stroke ; 7(4): 293-7, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22151911

ABSTRACT

BACKGROUND: The influence of lesion size and laterality on each component of the National Institutes of Health Stroke Scale has not been delineated. The objective of this study was to use perfusion-weighted imaging to characterize the association of ischaemic volume and laterality on each component item and the total score of the 10 s. Ordinal regression was used to clarify the relationship between ischaemic volume, laterality, and

Subject(s)
Brain Ischemia/pathology , Functional Laterality/physiology , Stroke/pathology , Aged , Brain Ischemia/physiopathology , Female , Humans , Magnetic Resonance Angiography , Male , Middle Aged , Muscle Weakness/etiology , Muscle Weakness/pathology , Prospective Studies , Psychomotor Disorders/etiology , Psychomotor Disorders/pathology , Stroke/complications , Stroke/physiopathology
9.
J Neurol Sci ; 313(1-2): 142-6, 2012 Feb 15.
Article in English | MEDLINE | ID: mdl-21945462

ABSTRACT

BACKGROUND: Early disruption of the blood-brain barrier (BBB) due to severe ischemia can be detected by MRI T2* permeability imaging. In middle cerebral artery (MCA) infarction, pretreatment T2* permeability derangements have been found in 22% of patients and are powerful predictors of hemorrhagic transformation after revascularization therapy. The frequency, clinical correlates, and relation to hemorrhagic transformation of permeability derangements in posterior circulation have not been previously explored, and may differ as ischemia volume and collateral status are different between vertebrobasilar and MCA infarcts. METHODS: We analyzed clinical and pretreatment MRI data on consecutive patients undergoing recanalization therapy for acute vertebrobasilar ischemia at a medical center November 2001 through September 2009. Pretreatment MRI permeability images were derived from perfusion source imaging acquisitions. Permeability abnormality was detected as persisting increased signal intensity at later time points in perfusion MRI acquisition, indicating local accumulation of contrast caused by BBB leakage. RESULTS: Among the 14 patients meeting study entry criteria, mean age was 71.1 years and median pretreatment NIHSS was 20.5. Permeability imaging abnormality was present in 1 of the 14 patients (7%). Among 14 patients, post-treatment parenchymal hematoma occurred in one and more minor degrees of hemorrhagic transformation in four. The one patient with pretreatment permeability abnormality was the patient to develop post-treatment parenchymal hematoma (Fisher's exact test, P=0.07). CONCLUSION: Pretreatment permeability abnormality, an indicator of BBB derangements, is an infrequent finding in acute posterior circulation ischemic stroke and may be associated with an increased risk of parenchymal hematoma development undergoing recanalization therapy.


Subject(s)
Blood-Brain Barrier/metabolism , Capillary Permeability/physiology , Cerebral Hemorrhage/metabolism , Stroke/metabolism , Vertebrobasilar Insufficiency/metabolism , Aged , Aged, 80 and over , Blood-Brain Barrier/pathology , Brain Ischemia/metabolism , Brain Ischemia/pathology , Cerebral Hemorrhage/pathology , Female , Humans , Ischemic Attack, Transient/metabolism , Ischemic Attack, Transient/pathology , Male , Middle Aged , Stroke/pathology , Vertebrobasilar Insufficiency/pathology
10.
World Neurosurg ; 76(6 Suppl): S16-23, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22182267

ABSTRACT

OBJECTIVE: Intracranial large-vessel ischemia is associated with poor clinical outcome and increased mortality. Early reperfusion of ischemic tissue remains the goal of treatment of stroke. Intravenous tissue plasminogen activator (IV tPA) has been shown to improve clinical outcomes for patients who experience ischemic stroke, but it has been shown to be less efficacious for large-vessel occlusions. Mechanical clot extraction provides a therapeutic option for those who are ineligible for, or who do not respond to, conventional ischemic stroke treatment. METHODS: We reviewed the initial studies of the Merci Retriever and Penumbra System for mechanical clot extraction. Baseline patient characteristics, as well as revascularization rates and clinical outcome, were examined. RESULTS: Baseline National Institutes of Health Stroke Scale scores were greater than those observed in previous IV tPA studies, consistent with large-vessel occlusion. Successful recanalization occurred more frequently than with IV tPA and was associated with improved clinical outcome and mortality. Symptomatic intracranial hemorrhage and mortality rates were greater than those seen with IV tPA. CONCLUSIONS: Mechanical clot extraction can be performed safely in patients with large-vessel occlusions, and successful recanalization resulted in better clinical outcomes than those without. Mechanical thrombectomy provides a therapeutic option for ischemic stroke patients who are ineligible for, or who do not respond to, IV thrombolytics. Further studies, including randomized clinical trials, are needed to validate these findings.


Subject(s)
Brain Ischemia/surgery , Clot Retraction , Stroke/surgery , Thrombectomy/methods , Thromboembolism/surgery , Brain Ischemia/complications , Brain Ischemia/mortality , Cerebral Revascularization , Embolectomy , Humans , Plasminogen Activators/therapeutic use , Randomized Controlled Trials as Topic , Stroke/etiology , Stroke/mortality , Thromboembolism/complications , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome , United States , United States Food and Drug Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...